<DOC>
	<DOCNO>NCT02374021</DOCNO>
	<brief_summary>In randomize controlled clinical trial , investigator compare effect [ 18F ] -fluorodeoxyglucose positron emission tomography-computed tomography ( FDG PET/CT ) two treatment regimen rheumatoid arthritis ( RA ) patient deem methotrexate inadequate responder ( MTX-IRs ) . Two common RA treatment compare : triple therapy ( sulfasalazine , methotrexate , hydroxychloroquine ) versus tumor necrosis factor ( TNF ) inhibitor ( etanercept adalimumab , plus background methotrexate ) .</brief_summary>
	<brief_title>Treatments Against RA Effect FDG-PET/CT</brief_title>
	<detailed_description>Consenting subject screen eligibility randomize treatment arm . Subjects randomized treatment arm either synthetic disease-modifying antirheumatic drug ( DMARDs ) [ triple therapy : sulfasalazine , methotrexate , hydroxychloroquine ] biologic DMARDs [ etanercept adalimumab , plus background methotrexate ] . Once randomize , baseline visit conduct subject . Baseline data collection include questionnaire , disease activity score , first FDG-PET/CT imaging . After baseline week 0 , subject visit rheumatologist week 6 , 12 , 18 , 24 safety lab collection disease activity score questionnaire . The second FDG-PET/CT perform week 24 . Blood specimen collect week 0 , 6 , 18 , 24 bioassay . Subject participation end week 24 visit . Patients care provider unblinded . The FDG-PET/CT image reader blind treatment arm well timepoint image acquisition .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>Fulfill American College Rheumatology/European League Against Rheumatism 2010 criterion RA Men ≥ 45 year woman ≥ 50 year MTX monotherapy ≥ 12 week ≥ 15mg weekly No nonbiologic DMARDs precede two month Disease Activity Score28 &gt; 3.2 Able sign inform consent Prior use biologic DMARD Current use &gt; 10mg per day prednisone Use statin lipid lower drug PCSK9 inhibitor past 12 month Prior patient report , physician diagnose clinical cardiovascular ( CV ) event Diabetes mellitus ( DM ) fast blood glucose &gt; 120mg/dL Systemic lupus erythematosus ( SLE ) autoimmune chronic inflammatory disease ( i.e . inflammatory bowel disease , sarcoidosis ) Cancer treat last 5 year ( except basal squamous cell ) lymphoma melanoma Known pregnancy , HIV , Hepatitis B Virus , Hepatitis C Virus , active ( untreated latent ) tuberculosis Baseline : liver , renal blood count abnormality , Glucose6phosphate dehydrogenase ( G6PD ) deficiency Known sulfa allergy , macular disease hypersensitivity treatment ; know demyelinate disease ; uncompensated Congestive Heart Failure ( CHF ) Intraarticular injection 4 week prior baseline FDG PET/CT 2 high dose radiation scan past year ( CT scan contrast , angiogram , SPECT nuclear medicine scan , myocardial/cardiac perfusion scan )</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>rheumatoid arthritis</keyword>
</DOC>